© 2020 MJH Life Sciences™ and Drug Topics. All rights reserved.
CBD
Stay Ahead of Trends in Dietary Supplements
September 07, 2020
What supplements are patients looking for the most, and how can pharmacists help?
FDA Approves CBD Treatment for Seizures in Rare Genetic Disease
August 04, 2020
The FDA approved a cannabidiol oral solution treatment (Epidiolex, Greenwich Biosciences) for seizures associated with tuberous sclerosis complex.
Cannabis Series: FDA Support, Research in the Works
July 31, 2020
Our first episode of our latest Cannabis Series is focused on the burgeoning medical marijuana landscape, featuring FDA's guidelines and research on the diverse benefits of cannabis as medicine.
FDA Releases Guidance To Boost Cannabis Clinical Research
July 27, 2020
Responding to growing interest by industry stakeholders, the agency has offered draft guidance outlining quality considerations and other practical recommendations for cannabis and cannabis-derived compounds.
Systematic Review Evaluates Cannabis, Cannabinoids in Palliative and Supportive Oncology Care
May 30, 2020
A systematic review of medical cannabis and cannabinoid use in oncology care demonstrated varied results.
DEA Deschedules Antiepileptic CBD Oral Solution Epidiolex
April 07, 2020
Cannabidiol oral solution (Epidiolex, GW Pharmaceuticals) is no longer considered a controlled substance.
6 Ways to Diversify Your Pharmacy's Revenue Streams
March 06, 2020
Strategies for seizing revenue opportunities outside of the PBM.
Epidiolex sNDA Seeking FDA Approval for Tuberous Sclerosis Complex Indication
February 04, 2020
A supplemental application for cannabidiol oral solution (Epidiolex, GW Pharmaceuticals and Greenwich Biosciences) has been submitted for the treatment of seizures associated with tuberous sclerosis complex.
Lack of Quality Evidence Around Cannabis Use Complicates Patient Management in the Health-System Setting
December 10, 2019
Takeaways from a roundtable at ASHP 2019.
FDA Warns Several Companies for Illegally Selling CBD Products
November 26, 2019
The FDA issued warning letters to several companies marketing their CBD products in ways that violate the Federal Food, Drug, and Cosmetic Act.